Reviewing Corbus Pharmaceuticals (NASDAQ:CRBP) and Shineco (NASDAQ:SISI)

Shineco (NASDAQ:SISI) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Valuation and Earnings

This table compares Shineco and Corbus Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shineco	$9.60 million	0.01	-$22.45 million	($204.00)	0.00
Corbus Pharmaceuticals	N/A	N/A	-$40.21 million	($5.51)	-2.08

Shineco has higher revenue and earnings than Corbus Pharmaceuticals. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Shineco has a beta of -0.91, indicating that its share price is 191% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500.

Profitability

This table compares Shineco and Corbus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shineco	-380.55%	-79.89%	-33.01%
Corbus Pharmaceuticals	N/A	-43.65%	-39.62%

Analyst Ratings

This is a summary of current recommendations and price targets for Shineco and Corbus Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shineco	1	0	0	0	1.00
Corbus Pharmaceuticals	2	0	8	1	2.73

Corbus Pharmaceuticals has a consensus price target of $44.38, suggesting a potential upside of 287.89%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Shineco.

Insider & Institutional Ownership

4.1% of Shineco shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 0.0% of Shineco shares are held by company insiders. Comparatively, 3.6% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Shineco on 10 of the 14 factors compared between the two stocks.

About Shineco

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.